Objective: To evaluate the efficacy, safety, and tolerability of long-term ziprasidone therapy in treatment-resistant schizophrenia.
Method: This prospective, 1-year, open-label study of ziprasidone (40-160 mg/day) was conducted in subjects who had participated in a previous randomized 12-week comparison of ziprasi-done and chlorpromazine in treatment-resistant schizophrenia (DSM-III-R criteria). The clinical response of 62 subjects was evaluated (32 subjects had been on ziprasidone treatment and 30 had been on chlorpromazine treatment prior to enrollment in the continuation study). Assessments included the Positive and Negative Syndrome Scale total and subscale scores, movement disorder scales, body weight, and laboratory measures. This study was conducted from May 2000 to April 2002.
Results: Thirty-three subjects (53%) completed 1 year of open-label ziprasidone therapy. Ziprasidone maintained clinical improvement (no significant symptom exacerbation) in 30 of 41 subjects (73%) who responded to the initial 12-week double-blind treatment with either ziprasidone or chlorpromazine. Ziprasidone did not increase body weight and was associated with a favorable metabolic profile during the continuation study period. There were no significant changes in standard movement disorder measures from the core study baseline during long-term ziprasidone treatment.
Conclusion: Ziprasidone was effective and well tolerated in the long-term therapy of patients with treatment-resistant schizophrenia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4088/jcp.v68n0902 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lateral Occipital Cortex as a Novel Target for Neuromodulation to Attenuate Auditory and Visual Hallucinations in a Patient with Ultra-treatment-resistant Schizophrenia: A Case Report.
Clin Psychopharmacol Neurosci
February 2025
Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, India.
Auditory/visual hallucinations and perceptual anomalies are one of the core symptoms experienced by patients with schizophrenia. Studies have implicated lateral occipital cortex (LOC) as one of the areas to be aberrantly functioning in schizophrenia, possibly associated with the auditory/visual symptoms of schizophrenia. Here we report of a case of a 29-year-old female diagnosed with treatment resistant schizophrenia on clozapine with persistent auditory verbal hallucinations (AVH) and visual anomalies.
View Article and Find Full Text PDFSchizophrenia and Bone Marrow Disorders: An Emerging Clinical Association.
Cureus
December 2024
Department of Psychiatry, Texas Tech University Health Sciences Center, Odessa, USA.
Schizophrenia is a chronic psychiatric disorder with a complex etiology involving genetic, neurobiological, and environmental factors. Many individuals with schizophrenia experience treatment resistance despite advances in pharmacologic and non-pharmacologic interventions. Immune dysregulation, characterized by altered cytokine levels, immune-related gene expression, and neuroinflammation, plays a critical role in schizophrenia's pathogenesis.
View Article and Find Full Text PDFClinical and Demographic Predictors of Early Clozapine Discontinuation Across Mood and Psychotic Disorders.
J Clin Psychopharmacol
January 2025
Department of Pharmacy, Mayo Clinic, Rochester, MN.
Background: Clozapine is effective for treatment-resistant schizophrenia and bipolar disorder but is often discontinued due to adverse effects. This study compared early clozapine discontinuation rates and reasons in patients with mood and psychotic disorders.
Methods: Data from all individuals with mood or psychotic disorders who initiated clozapine for the first time at the inpatient psychiatric unit of Mayo Clinic, Rochester, Minnesota, between 2014 and 2022 were retrospectively analyzed.
Early career psychiatrists' perceptions of and training experience in electroconvulsive therapy: A cross-sectional survey across Europe.
Eur Psychiatry
January 2025
Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Background: Electroconvulsive therapy (ECT) is a safe and effective treatment for several major psychiatric conditions, including treatment-resistant depression, mania, and schizophrenia; nevertheless, its use remains controversial. Despite its availability in some European countries, ECT is still rarely used in others. This study aims to investigate the experiences and attitudes of early career psychiatrists (ECPs) across Europe towards ECT and to examine how their exposure to ECT influences their perceptions.
View Article and Find Full Text PDFPrimary Cerebral Lymphoma With Isolated Vitreoretinal and Cerebral Recurrences Without Meningeosis: A Case Report.
Cureus
December 2024
Treatment Resistant Schizophrenia Outpatient Clinic, Júlio de Matos Hospital, São José Local Health Unit, Clinical Academic Center of Lisbon, Lisbon, PRT.
Primary central nervous system lymphoma (PCNSL) is a diffuse, large B-cell lymphoma affecting the brain, spinal cord, leptomeninges, or eyes. A patient with a recurrence of a previous PCNSL manifesting as an isolated vitreoretinal disease without central nervous system (CNS) involvement and a second cerebral recurrence without vitreoretinal involvement has not yet been reported. The patient is an 86-year-old man with PCNSL of the left cerebellum diagnosed at the age of 82 years and treated with suboccipital trepanation and resection of the lesion followed by chemotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!